July 19 Financial Quick Takes: Amarin raises cash ahead of Vascepa PDUFA date, plus Atara, Sunstone and Forendo
Ahead of Vascepa push, Amarin adds $400M to coffers
With the Sept. 28 PDUFA date looming for a potential expansion of the label for Vascepa icosapent to include reduced cardiovascular risk, Amarin Corp. plc (NASDAQ:AMRN) raised $400 million in a follow-on. The company sold 22.2 million ADSs at $18; the price represents a 15% discount to Amarin's closing price of $21.07 on Wednesday, when it proposed the offering after market hours. The company is doubling the size of its Vascepa sales force.
Atara raises $150M in upsized follow-on
Allogeneic T cell therapeutics company Atara Biotherapeutics Inc. (NASDAQ:ATRA) raised $150 million through the sale of 6.9 million shares and 2.9 million warrants at $15.28 in an upsized follow-on. The company's shares ended Thursday's session at $15.28; it proposed after hours to raise $125 million. Atara was off $0.27 to $15.01 in late afternoon trading Friday...